九强伟德国际1946

企业动态:雅培企业与伟德国际签订技术转让合作协议

发布于:2016-02-23

文章来源:

  雅培企业与伟德国际签订技术转让合作协议

  2016年2月24日,雅培企业与伟德国际在北京签署了战略性的生化诊断试剂《技术许可和转让合作协议》。此协议主要内容包括,伟德国际以技术(包括专利)许可的方式向雅培提供生化诊断试剂的生产配方及工艺控制流程;作为对价,雅培将提供一次性技术转让费用和里程碑付款,以及在未来一定时期内所转让伟德国际bv1946的销售提成。此次签约合作涉及的伟德国际bv1946达到55个,同时双方约定,雅培有权在伟德国际既有的在研伟德国际bv1946和将来新研发的伟德国际bv1946线中选择新增伟德国际bv1946。新增伟德国际bv1946的技术许可和转让将继续按照此协议约定模式实行。

  2013年底,伟德国际与雅培中国在北京正式签署生化试剂中国项目战略合作协议,经过2年多的合作,双方加深了解和信任,从而为此次进一步更紧密的合作奠定了基础。此次合作开创了中国IVD企业技术输出的先河,具有开创性历史意义;同时也契合了雅培在生化诊断做到全球领先的战略规划,强化了雅培在生化试剂领域的竞争优势。通过这一合作,雅培企业可以提供更多的生化试剂品种,从而为其用户提供更加完善和灵活多样的的生化检测菜单,使雅培企业不仅成为免疫诊断领域全球的领头羊,更通过此次合作,占据生化诊断领域的全球领先地位,对增强其在全球的竞争力具有重要意义。

  “雅培致力于为全球客户提供高质量的诊断伟德国际bv1946,从而帮助世界各地的人们获得健康,”雅培诊断业务运营副总裁Keith Cienkus表示,“大家期待和伟德国际紧密合作,伟德国际在生化试剂领域的领先技术,在中国良好的声誉以及发展前景,使其成为雅培强有力的合作方。此次合作也契合中国的医疗改革进程,借助雅培的全球平台和经验,帮助中国医疗器械生产企业更快的走向国际。”

  伟德国际董事长邹左军表示,“雅培企业是九强尊重的,也是国际公认的IVD行业领先企业,本次合作协议的签署标志着双方在已有良好合作的基础上,今后将逐步开展更深入的合作。通过此次合作,伟德国际提供的技术将有助于丰富雅培的生化诊断伟德国际bv1946线,同时,伟德国际亦将获得由此产生的销售提成,这将是一次令人愉快的双赢合作。”

 

  伟德国际曾参与国家863计划研发的多个项目。此次合作,伟德国际的伟德国际bv1946技术及质量控制体系被国际巨头认可,是对其专注生化诊断试剂,做到研发领先、技术领先、质量领先,达到国际**企业水平的**证明。此次合作不但为伟德国际未来业绩的持续稳定增长奠定了基础,也可以促进伟德国际新伟德国际bv1946的研发内生动力,从而继续巩固并保持在生化试剂领域内的领先地位。本次协议的签署是伟德国际走向国际市场的良好开端,为未来开拓国际市场奠定了重要的基础。

 

 

 

 

 

 

  关于雅培诊断业务

  雅培是全球体外诊断伟德国际bv1946领域的**,致力于提供医学检测服务,囊括了免疫测定、临床化学、血液学、血液筛查、分子学、生物鉴定学、床旁检测、信息学。大家的诊断解决方案不仅是一个测试或者数据点,其设计致力于在整个医疗保健系统内参与、影响、提高医疗决策和病人护理。如今,雅培诊断在体外诊断仪器、测试及相关的自动化和信息学等方面不断的发展并商业化,其诊断伟德国际bv1946广泛的使用在医院,参考实验室、医师办公室、急症室、重症监护和远程诊断中。雅培的诊断解决方案在全球超过100个国家拥有22,000个客户。

  关于雅培

  雅培,致力于健康,专注于生命,帮助更多人创造更多可能。125多年来,雅培把新的伟德国际bv1946和技术带向世界——从营养品,诊断,医疗器械,到药品——涵盖生命的每一个阶段,为生命创造更大可能。如今,雅培全球74,000名员工,正在为全世界150多个国家的人们生活得更健康和更美好而不懈努力。雅培在中国运营近20年, 拥有4000多名员工,总部位于上海。

  关于伟德国际

  伟德国际(以下简称“伟德国际”)是一家以生化诊断系统的研发、生产和销售为主营业务的高成长型企业,拥有与国际基本同步发展的系列伟德国际bv1946。伟德国际一直注重新伟德国际bv1946研发,在生化试剂领域具备很强的研发创新能力。作为国内同行业的领军企业,伟德国际具备生化诊断试剂全线伟德国际bv1946。除了质量优良的常规项目之外,伟德国际还拥有同型半胱氨酸、胱抑素C等优势突出的新项目。近几年来,企业始终保持着高速发展,生化系统的销售规模及盈利能力在我国体外诊断试剂行业中名列前茅。凭借着优异业绩和技术创新,伟德国际连续九年上榜“福布斯中国**潜力中小企业排行榜”,2014年10月30日,企业在创业板成功上市,股票代码为300406。


 

  Abbott & BSBE Partner on 

  Clinical Chemistry Technology Transfer Agreement

 

  (Feb 24th, 2016) Today, Abbott, the global health care company, and Beijing Strong Biotechnologies Inc. (“BSBE” for short) signed a strategic “Technology License and Transfer” Agreement in Beijing for Clinical Chemistry testing products. Under the terms of the agreement, BSBE will provide the license and technology to Abbott for Clinical Chemistry products currently manufactured by BSBE in China.  Abbott will pay for the technology License and Transfer with up-front and milestones payments as well as a royalty on sales for  a period of time. The agreement covers 55 products at the current stage, but it grants Abbott the right to add to the list more products from BSBE’s current and future pipelines. New products will continue to be transferred in line with the agreement. 

  Earlier, the two companies reached a strategic agreement in Beijing on clinical chemistry reagents in 2013. The two sides have since deepened mutual understanding and trust, which helps lay a solid foundation for further cooperation. Abbott and BSBE’s cooperation is a milestone for China’s IVD companies in technology transfer. It fits Abbott’s strategy to become a stronger player in the global biochemical reagent industry. This agreement enables Abbott to provide a more comprehensive clinical chemistry assay menu to laboratory customers. The cooperation also means significantly to Abbott’s competitiveness in the global market as it enables the company to be not only a world leader in immunoassay, but also a top-ranking supplier of biochemical diagnostic reagent. 

  “Abbott is committed to providing the high quality diagnostics products to our customers to help improve care for people around the world,” said Keith Cienkus, Divisional Vice President Diagnostics Operations, Abbott. “We look forward to a strong partnership with BSBE. Their deep expertise in clinical chemistry, strong reputation especially in China, and their long term vision makes them a od strategic partner for Abbott. The agreement is also in line with China’s healthcare reform. In particular, it is expected to help local medical device manufacturers expand footprint by leveraging Abbott’s global platform and expertise.” 

  "Abbott is a well-respected company and also a global leader in the IVD industry. We have already had fruitful cooperation in the past and the agreement will raise the curtain of further cooperation on the worldwide stage. BSBE's offer of technologies will help Abbott expand its range of biochemical diagnostic products. In return, BSBE will receive milestone payments and a royalty on the sales revenue in the global market. This will definitely be a win-win cooperation," said Zou Zuojun, President of BSBE.

  BSBE has been participated in several national 863 bioscience technological research projects. This new agreement honors BSBE’s specialization in biochemical diagnostic reagent to become a leader in R&D, technology as well as quality. The cooperation will not only lay the foundation for BSBE’s steady and stable growth in the future, but further boost the R&D capabilities to consolidate its leading position in the biochemical reagent business. The cooperation also unveils the globalization of BSBE and lays the foundation to explore the world market.

 

  About Abbott Diagnostics Business

  Abbott is a global leader in in vitro diagnostics offering a broad portfolio spanning immunoassay, clinical chemistry, hematology, blood screening, molecular, point of care and informatics. Our diagnostics solutions are more than just a test or data point, they are designed to anticipate, leverage and improve decision-making and patient care across the entire health care system. Today, Abbott’s Diagnostics businesses develop and commercialize in vitro diagnostics instruments, tests and related automation and informatics solutions for use in hospitals, reference labs, physician offices, emergency departments, critical care and remote settings. Our solutions are sold to more than 22,000 customers in more than 100 countries around the world.

  About Abbott

  At Abbott, we’re committed to helping you live your best possible life through the power of health. For more than 125 years, we’ve brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals that create more possibilities for more people at all stages of life. Today, 74,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

  Abbott has been operating in China for nearly 20 years and provides Chinese consumers with a diverse range of nutrition, pharmaceutical and medical products. Abbott has more than 4,000 employees in China and is headquartered in Shanghai.  

  About BSBE

  BSBE is a fast developing company that focuses on the R&D, production and sales of biochemical diagnostic reagent. BSBE boasts strong R&D capabilities in biochemical reagent with its consistent pursuit of new products. As an industry pioneer in China, the company owns a full range of biochemical diagnostic reagent products. Apart from regular projects featuring premium quality, BSBE possesses small but prominent new ones such as homocysteine, Cystatin C. The company‘s sales and profitability of biochemical products are top-ranked in China’s in vitro diagnostic reagent business over the last few years. It is also named for nine straight years by Forbes as one of China’s most promising SMEs thanks to its excellent performances and technological innovation. BSBE is listed on the growth enterprise board. Its stock code is 300406. 

 
XML 地图 | Sitemap 地图